Renal Diseases Drug Development Pipeline Review: 2018 - Therapeutics Under Development and Key Players Involved - ResearchAndMarkets.com

January 11, 2019

DUBLIN--(BUSINESS WIRE)--Jan 11, 2019--The “Renal Diseases Drug Development Pipeline Review, 2018” report has been added to ResearchAndMarkets.com’s offering.

Renal Diseases Drug Development Pipeline Review, 2018 provides an overview of the pipeline landscape for renal diseases.

It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products.

Chronic kidney disease is the slow loss of kidney function over time: There are 58 products in development for this indication. Accumulation of extracellular matrix in the kidney: There are 49 products in development for this indication. Polycystic kidney disease: There are 26 products in development for this indication. End-stage kidney disease: There are five products in development for this indication.

Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.


Which companies are the most active within each pipeline? Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication? To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies? What are the most important R&D milestones and data publications to have happened in this disease area?

Topics Covered

1 Table of Contents

2 Introduction

3 Therapeutics Development

4 Therapeutics Assessment

5 Companies Involved in Therapeutics Development

6 Dormant Projects

7 Discontinued Products

8 Product Development Milestones

Companies Profiled

AdAlta Ltd Allena Pharmaceuticals Inc apceth Biopharma GmbH Arch Biopartners Inc Astellas Pharma Inc AstraZeneca Plc Bayer AG Corvidia Therapeutics Inc DiaMedica Therapeutics Inc DiscoveryBiomed Inc DURECT Corp Epigen Biosciences Inc Galectin Therapeutics Inc GenKyoTex SA GNI Group Ltd iBio Inc IC-MedTech Inc Ipsen SA KBP BioSciences Co Ltd Kidney Fibrosis ManRos Therapeutics Mironid Ltd NovaTarg Therapeutics Inc Novo Nordisk AS OPKO Health Inc Opsidio LLC Otsuka Holdings Co Ltd Pharmaxis Ltd Q BioMed Inc Redx Pharma PLC Unity Biotechnology Inc Vascular Biogenics Ltd Vascular BioSciences Vicore Pharma AB and more...

For more information about this report visit https://www.researchandmarkets.com/research/jh93df/renal_diseases?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005123/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Drug Discovery,Liver and Kidney Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/11/2019 05:48 AM/DISC: 01/11/2019 05:48 AM


Update hourly